Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft

NACompletedINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

August 31, 2018

Study Completion Date

February 28, 2021

Conditions
StenosisRestenosis
Interventions
DEVICE

Covera Vascular Covered Stent following PTA

Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.

PROCEDURE

Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon

Treatment of stenoses with PTA only

Trial Locations (24)

2025

Middlemore Hospital, Auckland

3000

University Hospital Leuven, Leuven

5042

Flinders Medical Centre, Bedford Park

5068

Royal Adelaide Hospital, Kensington Gardens

6202

Maastricht Universitair Medish Centrum, Maastricht

8036

LKH-Univ. Klinikum Graz, Graz

8091

Universitaets Spital Zurich, Zurich

19713

Nephrology Associates, P.A., Newark

27607

NC Heart and Vascular Research, Raleigh

27610

NC Nephrology, Raleigh

32207

Jacksonville Center for Clinical Research, Jacksonville

32216

First Coast Cardiovascular Institute, Jacksonville

34471

Ocala Kidney Group, Ocala

46202

Indiana University Hospital, Indianapolis

60521

Chicago Access Care, Chicago

76104

Tarrant Vascular Clinic, Fort Worth

78215

Clinical Advancement Center, PLLC, San Antonio

80112

Radiology Imaging Associates, Englewood

85281

Southwest Vascular Center, Tempe

92653

Alliance Research Centers, Laguna Hills

97080

Universitätsklinikum Würzburg, Würzburg

06520

Yale University & Yale New Haven Hospital, New Haven

01089

Renal and Transplant Associates of New England, P.C., West Springfield

02906

Providence Access Care, Providence

Sponsors

Lead Sponsor

All Listed Sponsors
lead

C. R. Bard

INDUSTRY

NCT02649946 - Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft | Biotech Hunter | Biotech Hunter